Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +45

Moderna Inc. stock gains on cancer vaccine progress and strong rally

AI-generated analysis

📈 Moderna stock rallied strongly to close at USD 154.03 on September 18, 2026, fueled by positive Phase 3 data for a personalized cancer vaccine.

🔬 The company is increasingly being valued as an oncology-focused biotechnology firm rather than just a pandemic-vaccine developer.

💰 Moderna's market capitalization reached approximately USD 61.50 billion following the sharp price increase.

⚠️ The company reported trailing twelve-month earnings per share of negative USD 7.99, maintaining a loss-making profile.

📉 Consensus analyst price targets stand at USD 76.72, implying roughly 50% downside from the current trading level.

📊 The current valuation suggests a premium of about 100% over where analysts average see the stock in the medium term.

🔄 Investors are reassessing Moderna's long-term pipeline potential based on convincing clinical trial results for cancer therapy.

Bullish Signals
  • Moderna stock gained significantly, closing at USD 154.03 on September 18, 2026, driven by positive Phase 3 data for a personalized cancer vaccine.
  • The company is successfully transitioning from a pandemic-vaccine narrative to being valued as an oncology-focused biotechnology company with broader mRNA applications.
Risk Factors
  • Moderna maintains a loss-making profile with trailing twelve-month earnings per share of negative USD 7.99, indicating dependence on future revenue conversion.
  • The consensus analyst price target of USD 76.72 is roughly 50% below the current closing price, suggesting analysts see significant downside risk from current levels.
Full Analysis
Moderna Inc. stock closed at USD 154.03 on the Nasdaq on September 18, 2026, marking a strong rally driven by positive Phase 3 clinical data for a personalized cancer vaccine. This progress has shifted investor perception away from the pandemic-vaccine narrative, repositioning the company as an oncology-focused biotechnology firm with broader mRNA applications. Despite the significant share price appreciation, the company maintains a loss-making profile with trailing twelve-month earnings per share of negative USD 7.99. The current market capitalization of approximately USD 61.50 billion implies a valuation premium of roughly 100% over the consensus analyst price target of USD 76.72, highlighting a divergence between short-term momentum and medium-term fundamental expectations. Analysts view the stock as dependent on converting its pipeline products into sustainable revenue streams to justify the elevated price levels. While trading near recent highs, the shares have shown volatility, with some data snapshots indicating minor intraday fluctuations around the mid-150 dollar range following the initial rally.